Saturday, May 13, 2023 3:45 PM – 5:45 PM ET Room 206
Block Symposium
Novel Therapeutic Targets for Controlling Immune Responses and Dampening Inflammation
Chairs
- Brad Hoffman, Univ. of Florida
- Steven Kerfoot, Univ. of Western Ontario
Speakers
- Joshua A. Taylor, NIA NIH, Unmasking arterial-resident autoreactive B cells involved in atherosclerosis and peripheral Artery disease progression
- Maroua Ferhat, OncoOne Res. & Dev. GmbH, Austria, ON104, a novel antibody targeting oxidized macrophage migration inhibitory factor (oxMIF) shows efficacy in preclinical models of chronic inflammation
- Amber Simone Griffith, Washington Univ. Sch. of Med. in St. Louis, Selective targeting of auto reactive B cells using bispecific molecules
- Shaikh Nisar Ali, Long Island Univ., 1,25-dihydroxy vitamin D enhances the differentiation of intestinal stem cells Ex Vivo and In Vivo
- Steven Kerfoot, Univ. of Western Ontario, Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity
- Lauren Stewart Stafford, Univ. of Florida, Novel bio-signature for the topical administration of a suppressor of cytokine signaling-1 mimetic to the equine eye: implications in treatment of recurrent uveitis (RU)
- Gaurav Kumar, Oklahoma Med. Res. Fndn., BAFF and APRIL signaling through BCMA regulates microglial cells in the central nervous system.
- Insha Zahoor, Henry Ford Health, Pro-resolution lipid mediator maresin-1 reduces inflammation, promotes neuroprotection, and prevents disease progression in multiple sclerosis model of autoimmunity
